CGT in Dry Age-related Macular Degeneration & Hematological Disorders in India

When:  Jul 10, 2024 from 10:30 to 11:30 (IST)

Contact

Elizabeth Lam

Elizabeth@isctglobal.org


Current status of Cell & Gene Therapy in Dry Age-related Macular Degeneration and Hematological Disorders in India

Presented by the ISCT Asia Regional Executive Committee 
Sponsored by Eyestem Research Pvt Ltd 

 

Progress of cell and gene therapy in India with clinical trials in eye disorder (Dry Age-related Macular Degeneration) and Gene Therapy trials in different hematological disorders.


Key Learning Objectives: 
  • Understanding the current landscape of cell and gene therapy research and development in India.
  • Exploring the progress and challenges of clinical trials in treating Dry Age-related Macular Degeneration (AMD) using cell and gene therapy approaches.
  • Examining the advancements and outcomes of gene therapy trials targeting various hematological disorders in India.
  • Assessing the potential of cell and gene therapy as innovative treatment modalities for AMD and hematological disorders.
  • Engaging in discussions regarding the role of collaboration between academia, industry, and government in advancing cell and gene therapy research and implementation in India.

Chairs:

Dr. Xinyi Su , PhD, MMed, FAMS, MBChir

Senior Consultant in Vitreo-Retinal Surgery,

National University Hospital,

Singapore









Dr. Pawan Kumar Gupta, MBBS, MD, DNB, PhD

ISCT Asia Regional VP-Elect

President – Medical & Regulatory Affairs,

Stempeutics Research,

India

Speakers:

Dr. Jogin Desai, MD

Founder & CEO,

Eyestem,

India

Founder & Chief Executive Officer Dr. Desai is the founder and CEO of Eyestem, a company aiming to democratise access to cell therapy through a scalable cell therapy platform. He brings more than 20 years of experience in growing and nurturing businesses to his newest venture. Prior to Eyestem, he was part of the global leadership team at Quintiles and headed up their cardiac safety business from 2001 to 2007. More recently, he was the CEO of Cenduit (www.cenduit.com) , a randomization joint venture between Quintiles (IQVIA) and ThermoFisher Scientific company with offices in North Carolina, Bangalore, Basel and Philadelphia.

Prof. Alok Srivastava, MD, FRACP, FRCPA, FRCP

Senior Professor,

Dept. of Haematology, Christian Medical College

India

Alok Srivastava, is Senior Professor in the Department of Haematology, Christian Medical College (CMC), Vellore, India and Head of the Centre for Stem Cell Research, a unit of Institute of Stem Cell Research and Regenerative Medicine (inStem), Bengaluru, at Vellore. 

Prof. Srivastava has been involved with clinical haematopoietic stem cell transplantation (HSCT) at CMC, Vellore in India for nearly three decades. Over the last fifteen years, he has also established the Centre for Stem Cell Research which is focused on translational research to develop novel cell and gene therapies. 

He is the President of the Indian Society for Blood and Marrow Transplant and also the Chairman of the Executive Board of the Asia Pacific Blood and Marrow Transplant Group. He is the chair of the Technical Evaluation Committee for human genetics, genome engineering and nano technology applications of the Department of Biotechnology of the Ministry of Science and Technology, Government of India. 

Prof. Srivastava’s research interests in this field have haematopoietic stem cell transplantation, haemostasis disorders and gene therapy. His group has developed novel technologies for gene therapy for haemophilia and the major haemoglobin disorders – thalassemia major and sickle cell disease. He has initiated a first-in-human lentiviral vector mediated haemtopoietic stem cell-based gene therapy for haemophilia A in India. He has over 400 peer reviewed scientific publications. 

















Location

Online Instructions:
Url: http://us06web.zoom.us/webinar/register/WN_-JDJ577VRcGKc2bzEJS22w
Login: Register using the below link